- Home
- MDCX vs RNXT Comparison
MDCX vs RNXT Comparison
Compare MDCX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- RNXT
- Stock Information
- Founded
- MDCX 2008
- RNXT 2012
- Country
- MDCX Canada
- RNXT United States
- Employees
- MDCX N/A
- RNXT N/A
- Industry
- MDCX
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- MDCX
- RNXT Health Care
- Exchange
- MDCX Nasdaq
- RNXT Nasdaq
- Market Cap
- MDCX 33.8M
- RNXT 34.0M
- IPO Year
- MDCX N/A
- RNXT 2021
- Fundamental
- Price
- MDCX $3.44
- RNXT $1.02
- Analyst Decision
- MDCX Strong Buy
- RNXT Strong Buy
- Analyst Count
- MDCX 1
- RNXT 1
- Target Price
- MDCX $10.00
- RNXT $9.00
- AVG Volume (30 Days)
- MDCX 110.8K
- RNXT 134.5K
- Earning Date
- MDCX 01-01-0001
- RNXT 05-09-2025
- Dividend Yield
- MDCX N/A
- RNXT N/A
- EPS Growth
- MDCX N/A
- RNXT N/A
- EPS
- MDCX N/A
- RNXT N/A
- Revenue
- MDCX N/A
- RNXT N/A
- Revenue This Year
- MDCX N/A
- RNXT N/A
- Revenue Next Year
- MDCX N/A
- RNXT N/A
- P/E Ratio
- MDCX N/A
- RNXT N/A
- Revenue Growth
- MDCX N/A
- RNXT N/A
- 52 Week Low
- MDCX $1.80
- RNXT $0.77
- 52 Week High
- MDCX $4.99
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- MDCX N/A
- RNXT 46.22
- Support Level
- MDCX N/A
- RNXT $0.91
- Resistance Level
- MDCX N/A
- RNXT $1.03
- Average True Range (ATR)
- MDCX 0.00
- RNXT 0.07
- MACD
- MDCX 0.00
- RNXT 0.01
- Stochastic Oscillator
- MDCX 0.00
- RNXT 77.78
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.